The FDA is holding a public advisory committee meeting next month to determine whether the categorisation of Dexcom 's new series Continuous Glucose Monitoring System ( CGM ) can change from a tracking device only to a continuous glucose monitor that can be used for regulatory decisions . The device sends glucose data directly to iOS smartphones via a built - in Bluetooth capability , eliminating the need for a separate receiver device .
The FDA is holding a public advisory committee meeting next month to discuss whether the categorisation of Dexcom's G5 Mobile Continuous Glucose Monitoring System (CGM) can change from a tracking device only to a blood glucose meter that can be used for treatment decisions. The device sends glucose data directly to iOS smartphones via a built-in Bluetooth capability, eliminating the need for a separate receiver device.